Comparison of Plaque- and Flow Cytometry-Based Methods for Measuring Dengue Virus Neutralization

ABSTRACT As dengue vaccines enter clinical trials, there is a need for rapid and quantitative assays to measure neutralization. We have developed flow-based neutralization assays which generated results similar to those generated by the established, plaque reduction neutralization test. The flow assays are an improvement, as they use human cells and allow for high-throughput screening.

[1]  Jorge Pardo,et al.  An immunocytometric assay based on dengue infection via DC-SIGN permits rapid measurement of anti-dengue neutralizing antibodies. , 2006, Journal of virological methods.

[2]  R. Doms,et al.  A rapid and quantitative assay for measuring antibody-mediated neutralization of West Nile virus infection. , 2006, Virology.

[3]  A. Nisalak,et al.  Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection. , 2005, The Journal of infectious diseases.

[4]  R. Johnston,et al.  Flow Cytometry-Based Assay for Titrating Dengue Virus , 2005, Journal of Clinical Microbiology.

[5]  P. Desprès,et al.  Dendritic Cell-specific Intercellular Adhesion Molecule 3-grabbing Non-integrin (DC-SIGN)-mediated Enhancement of Dengue Virus Infection Is Independent of DC-SIGN Internalization Signals* , 2005, Journal of Biological Chemistry.

[6]  Anavaj Sakuntabhai,et al.  A variant in the CD209 promoter is associated with severity of dengue disease , 2005, Nature Genetics.

[7]  J. Stephenson.  Understanding dengue pathogenesis: implications for vaccine design. , 2005, Bulletin of the World Health Organization.

[8]  B. Guy,et al.  Evaluation by flow cytometry of antibody-dependent enhancement (ADE) of dengue infection by sera from Thai children immunized with a live-attenuated tetravalent dengue vaccine. , 2004, Vaccine.

[9]  P. Desprès,et al.  Dendritic‐cell‐specific ICAM3‐grabbing non‐integrin is essential for the productive infection of human dendritic cells by mosquito‐cell‐derived dengue viruses , 2003, EMBO reports.

[10]  J. Mascola,et al.  Human dendritic cells as targets of dengue virus infection. , 2001, The journal of investigative dermatology. Symposium proceedings.

[11]  D. Vaughn,et al.  Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. , 2001, The American journal of tropical medicine and hygiene.

[12]  Michael S. Diamond,et al.  Modulation of Dengue Virus Infection in Human Cells by Alpha, Beta, and Gamma Interferons , 2000, Journal of Virology.

[13]  A. Nisalak,et al.  Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. , 1988, The American journal of tropical medicine and hygiene.

[14]  A. Allison,et al.  Dengue viruses and mononuclear phagocytes. II. Identity of blood and tissue leukocytes supporting in vitro infection , 1977, The Journal of experimental medicine.

[15]  A. Nisalak,et al.  A plaque reduction test for dengue virus neutralizing antibodies. , 1967, Journal of immunology.

[16]  R. Dulbecco,et al.  A study of the basic aspects of neutralization of two animal viruses, western equine encephalitis virus and poliomyelitis virus. , 1956, Virology.

[17]  Charles M. Rice,et al.  Flaviviridae :T he Viruses and Their Replication , 2007 .

[18]  Q. Sattentau,et al.  Mechanisms of virus neutralization by antibody. , 2001, Current topics in microbiology and immunology.

[19]  R. Schlesinger,et al.  Dengue Viruses , 1977, Virology Monographs Die Virusforschung in Einzeldarstellungen.